PERSONAL INFORMATION

- Name: Abdel-Aziz Awad Zidan
- Date of Birth: July 26, 1984
- Place of Birth: Al-Gharbia, Egypt
- Citizenship: Egyptian
- Marital Status: Married with two children
- Phone: Mobile: +2-012-02435243
  Home: +2-040-5709006
- Email: CECR_a.zidan@unv.tanta.edu.eg
  Sherif_zidane2020@yahoo.com
- Current Position: Director of Genomics & Proteomics unit,
  Center of Excellence for Cancer Research (CECR), Tanta University
- Current Work addresses: Tanta University Educational Hospital, Medical campus, Tanta 31527, Al-Gharbia, Egypt

EDUCATION

- **High School Diploma** 9/1998- 6/2001
  Khalid Bin Al-waleed Sec. School, Al-Ain, United Arab Emirates
- **B.Sc., Biology, General Zoology** 9/2001-11/2005
  Faculty of Science, Tanta University, Egypt
- **Post-graduate Diploma, Medical Analytical Biochemistry** 9/2006-6/2007
  Faculty of Science, Menufiya University, Egypt
- **M.Sc., Physiology** 9/2006-6/2010
  Faculty of Science, Tanta University, Egypt
- **Ph.D., Physiology - Immunology** 7/2011-10/2013
  Department of Hematology-Oncology, University of Miami, USA and Faculty of Science, Tanta University, Egypt

THESIS

- **M.Sc.:** Chemotherapeutic studies on helminthic infections in laboratory animals. Tanta University, Faculty of Science, Egypt, June 2010
- **Ph.D.:** Generation of T cells with stem cell –like phenotype for anti-tumor adoptive immunotherapy. University of Miami, FL, USA, and Tanta University, Faculty of Science, Egypt, October 2013.

ACADEMIC POSITIONS

- **Research Instructor** 12/2005-3/2009
  Faculty of Science, Tanta University, Egypt
- **Research Associate 1** 4/2009-6/2009
  University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Dodson Interdisciplinary Immunotherapy Institute Miami, FL, USA
- **Research Associate 2** 6/2009- 12/2010
  University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Dodson Interdisciplinary Immunotherapy Institute, Miami, FL, USA
- **Research Associate 3** 12/2010- 6/2012
  University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Dodson Interdisciplinary Immunotherapy Institute, Miami, FL, USA
- **Researcher** 6/2012 ~ Present
  Faculty of Science, Tanta University, Egypt
- **Director of Genomics & Proteomics unit** 6/2013 ~ Present
  Center of Excellence for Cancer Research (CECR), Tanta University, Egypt

PROFESSIONAL SOCIETES MEMBERSHIPS

- American Association of Cancer Research (AACR)
- American Association of Immunologist (AAI)
- American Physiological Society (APS)
- The Association of African Biomedical Scientists, Inc. (AABS)
- Egyptian Society of Experimental Biology (ESEB)
- Egyptian syndicate of scientific professions (Specialist medical analysis)

TEACHING EXPERIENCE: LECTURE

- **Clinical Biochemistry** 2007-2008
  Post-graduate students (Diploma of Biological analysis) at Faculty of Science, Tanta University, Egypt
- **Toxicology** 2007-2009
  Post-graduate students (Diploma of Biological analysis) at Faculty of Science, Tanta University, Egypt

TEACHING EXPERIENCE: LABORATORY

- **Practical Animal Physiology** 2006-2007
  Undergraduate Students at Faculty of Science, Tanta University, Egypt
- **Practical Immunology and Molecular Biology** 2009-2012
  Summer undergraduate student volunteer at University of Miami, Miller School of Medicine, Miami, FL, USA

TECHNICAL EXPERTISE

- Processing, Isolation, cryopreservation, and Thawing of Human Peripheral Blood Mononuclear cells (PBMCs) and Plasma
- Plasmid or cosmid DNA purification using QIAGEN plasmid Miniprep, Maxi, and Mega kit.
- Recovering plasmid DNA and Restriction analysis for plasmid verification
- Total RNA isolation using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
- cDNA synthesis using the Omniscript Reverse Transcriptase
- Real time PCR, RT-PCR.
- Isolation of high molecular weight DNA from biopsies
- Transfection of mammalian cell lines and nucleic acids into eukaryotic cells
- Transformation of DNA using one shot TOP10 E. coli
- Preparation of vaccine using different adjuvants and 4-way stopcock
- Harvesting, preparation of single cell suspension of lymph nodes, spleens, livers, thymus, and lungs.
- Enrichment of immune cells from lymphoid and non-lymphoid tissues.
- Histological preparations.
- Microsurgery including adrenalectomy and splenectomy.
- ELISA, ELISA spot.
- Magnetic cell sorting (MACS and beads sorting).
- Flow cytometry and Flow cytometric beads array.
- Cytolytic and proliferation assays.
- Intracellular flow cytometry assays.
- Generation of dendritic cells from bone marrow by GM-CSF/IL-4 culture.
- Cell culture of normal and tumor cells in vitro.
- Tumor assays including in vivo tumor growth and metastasis.
- Adoptive transfer of immune and tumor cells intravenously.
- Intra-peritoneal, subcutaneous, intramuscular, IV Injection and oral injections.
- Good user to flow cytometer, Colorimeter, Spectrophotometer, Flame-photometer.

- Performing all the biochemical and hematological assay in vitro
- Reagents preparation related to biochemical and biological assays
- Handling, breeding, screening of wild type, transgenic and knockout mice

TRAINING COURSES

- **Course in the Protection of Human Research Subjects** (CITI-Collaborative Institutional Training Initiative)
- **Biomedical Responsible Conduct of Research Course 1., Basic (RST501)** (CITI)
- **Responsible Conduct of Research CITI Health Information Privacy and Security (HIPS)** (CITI)
- **HSRO Integrity Program** (UM - University of Miami)
- **HIPAA - Business Associate B.A. Training** (Benefits Administration - UM)
- **PIM I - Role of the Manager** (Leadership Academy - PIM - UM)
- **PIM II - Performance Improvement Management** (Leadership Academy - PIM - UM)
- **Career Development** (Leadership Academy- UM)
- **Clinical Research Subject Enrollment Tracking** (Research Administration and Sponsored Programs- UM)
- **Web Animal Orders** (Research Administration and Sponsored Programs- UM)
- **Velos Patient Management Module** (Research Administration and Sponsored Programs- UM)
- **HIPAA Privacy & Security Awareness** (Benefits Administration- UM)
- **OSHA's TB, Bloodborne Pathogens and Biomedical Waste Training CBL**(EHS- UM)
- **Working with the IACUC** (CITI)
- **Essentials for IACUC Members** (CITI)
- **Aseptic Surgery** (CITI)
- **University of Miami, OH&S and SOPs** (CITI)
- **Informed Consent Course** (CITI)
- **Responsible Conduct of Research for Science Administrators** (CITI)
- **Research and Data Protection (UM)** (CITI)
- **CITI Health Information Privacy and Security (HIPS) for Clinical Investigators** (CITI)
- **CITI Health Information Privacy and Security (HIPS) for Clinicians** (CITI)
- **CITI Health Information Privacy and Security (HIPS) for Fundraisers** (CITI)
- **CITI Health Information Privacy and Security (HIPS) for Marketers, Basic Course** (CITI)
- **CITI Health Information Privacy and Security (HIPS) for Students and Instructors**(CITI)
- **GCP for Investigators and Staff, Basic Course** (CITI)
- **Investigators, Staff and Students, Basic Course** (CITI)

- **CITI Good Clinical Practice** (CITI)
- **Working with Amphibians in Research** (CITI)
- **Working with Mice in Research** (CITI)
- **Reducing Pain and Distress in Mice and Rats** (CITI)
- **Working with the Laboratory Rat** (CITI)
- **Working With Gerbils in Research Settings** (CITI)
- **Working With Hamsters in Research Settings** (CITI)
- **Working With Guinea Pigs in Research Settings** (CITI)
- **Working With Rabbits in Research Settings** (CITI)
- **Working With Cats in Research Settings** (CITI)
- **Working with Dogs in Research** (CITI)
- **Working With Swine in Research Settings** (CITI)
- **Working With Non-Human Primates in Research Settings** (CITI)

RESEARCH INTERESTS

Preclinical research:

- In vitro conditioning of T cells to acquire phenotypic and functional characteristics with hematopoietic stem cells
- Optimizing adjuvanticiy of combinatorial chemotherapy and adoptive immunotherapy.
- Development of novel delivery strategy for DNA vaccine and cytokines for utilization in cancer and infectious diseases.
- Optimizing combined treatment with dendritic cell-based vaccination and Cytokine Immunotherapy

Clinical research:

- Exploring the role of Myeloid derived suppressor cells (MDSCs) on the immune system in adult and pediatric patients with cancer
- Exploring the link between the immunosuppressive immature myeloid cells in breast cancer patients and the impact of inflammatory cytokines in their differentiation to beneficial cells
- Developing novel clinical strategies for Programming of $CD8^+$ T cells for successful ACT therapy in cancer patients
- Phase I drug development in solid tumors

RESEARCH SUPPORT (GRANTS)

Ongoing Research support

1. **Title: Genetic Signature center for fostering next generation translational cancer research (Project ID#:CEP1-038-TAN)**

Source: The Egyptian Ministry of Higher Education, Management of supporting Excellence (MSE)

Goal: The major goal of this project is to establish the "Next generation translational Cancer Research Center (NGTCRC) to utilize Genetic Signature for fostering next generation translational cancer research and as a new promising therapeutic strategy for clinical utility in patient classification, diagnosis, and individualized treatment.

Funding period: 1/1/2014 – 1/1/2016

Fund: 4,000,000 EGP

Role: Head of the Executive Teams of Research Outputs

2. **Title: Establishing Center of Excellence of Cancer Research (CECR) at Tanta University (Project ID#: 5245)**

Source: The Egyptian Ministry for Scientific Research, Science and Technology Development Fund (STDF)

Goal: The major goal of this project is to establish the "Center of Excellence in Cancer Research (CECR) to carry out internationally recognized research in molecular cell biology and immunology in general and in cancer in particular. The main themes are: 1) Cellular and Molecular Immunology; 2) Cancer Genetics; 3) HLA typing; and 4) DNA sequencing.

Funding period: 24/6/2013 – 23/6/2016

Fund: 9,650,000 EGP

Role: Co-Investigator

3. **Title: Dysfunctional myeloid cells as a predictor of failure of chronic HCV patients to interferon therapy (Project ID# 1469)**

Source: The Egyptian Ministry for Scientific Research, Science and Technology Development Fund (STDF)

Goal: The major goal of this project is to identify the dysfunctional features of the myeloid cells, including MDCS and DCs as potential predictor to the failure of IFN-α therapy and the development of persistent HCV infection in Egyptian patients.

Funding period: 30/8/2010 – 30/6/2014

Fund: 1,736,160 EGP

Role: Co-Investigator

4. **Title: Using biotechnological approach for mRNA-based vaccination in cancer immunotherapy**

Source: Research fund, Tanta University, Egypt

Goal: The major goal of this project is to enhance the potency of RNA-based vaccines that can potentially be applied to cancer vaccination systems with a tumor-associated antigen to be conducted for most cancer vaccinations.

Funding period: 1/1/2013 – 1/1/2015

Fund: 100,000 EGP

Role: Co-Investigator

5. **Title: The use of stem cells from Egyptian patients with chronic HCV to generate functional dendritic cells for immunotherapy**

Source: Research fund, Tanta University, Egypt

Goal: The major goal of this project is to correct the dysfunction in dendritic cells in HCV patients by generation of healthy dendritic cells from stem cells.

Funding period: 1/1/2013 – 1/1/2015

Fund: 100,000 EGP

Role: Co-Investigator

Completed Research Support

1. **Title: Programming T cell for Successful Adoptive Cell Therapy (K01CA134927)**

Source: National Institutes of Health (NIH) - National Cancer Institute (NCI) - USA

Goal: Define the contribution of homing to the lymph node to the survival and maturation of transferred TEA; 2) Ascertain if enhanced survival of TEA is due to their plasticity conferring a competitive advantage for cytokine sinks; 3) Determine the impact of enhanced TEA on the generation of T cell memory; 4) Test the impact of activation in the presence of IL-12 on the phenotypic and functional characteristics of human TCR transduced cells.

Funding period: 7/1/2009 – 2/6/2012

Role: Co-Investigator

2. **Title: Preclinical Development of a novel biopolymer nano-gel delivery system for DNA vaccines against breast cancer**

Source: Sylvester Braman Family Breast Cancer Institute's Women's Cancer League, USA

Goal: Determine the impact on immunogenicity and therapeutic efficacy of a DNA vaccine comprised of plasmids encoding fragments of CEA, HER-2, and TERT when delivered concomitantly with the adjuvants Poly-IC or CPG using the F2-gel delivery platform; 2) To determine the impact of a persistent and localized inflammatory response induced by the paracrine release of GM-CSF formulated into the F2 nano-gel on the immunogenicity and therapeutic efficacy of the DNA vaccine.

Funding period: 7/01/2010 – 6/30/2012

Fund: 50,000 USD
Role: Co-Investigator

3. **Title: Phase II Study of Neoadjuvant Treatment with NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients with Stages IIB-IIIC Breast Cancer (CTO#101072/Novelos)**
   Goal: Identify whether NOV-002, a stabilized form of glutathione disulfide (GSSG), enhances the effect of cytotoxic chemotherapy due to the known immunomodulatory properties of GSSG; and whether serum drug-induced glutathionylated proteins can be identified in human breast cancer patients that correlate with clinical response.
   Funding period: 6/2009 – 6/2012
   Role: Co-Investigator

4. **Title: Evaluation of F2 gel/IL-12-based vaccination on hepatic fibrosis and protection after Schistosoma mansoni infection**
   Source: Marine Polymer Technologies Inc., Danvers, Massachusetts, USA
   Goal: The major goal of this project was to develop F2 gel/IL-12 as a novel strategy for schistosoma vaccine
   Funding period: 1/6/2004-30/3/2007
   Role: Research Associate

WORKSHOPS AND SEMINARS

1- **Nucleic Acid Extraction Technology Seminar. Nucleic Acid Extraction Technology Using Extremophiles: Single Cells to Tail Tips.** Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., USA. January 21st, 2010
2- **Oncogenomics Core Facility seminar (IVIS spectrum seminar).** Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., USA. February 3rd, 2010
3- **qPCR seminar (Data Analysis made easy using Real Time StatMiner ®).** Diabetes Research Institute, University of Miami, Miami, FL., USA. February 24th 2010
4- **Characterization of NSG-hu mice.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. February 22nd 2010
5- **Role of vGPCR-mediated activation of Rac1 in Kaposi's sarcoma.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. March 1st 2010
6- **TARGETING LEUKOCYTE TRAFFIC IN IBD.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. March 8th 2010

7- **The role of IL-2/IL-2R signaling in Tregs development, homeostasis and function.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. March 22nd 2010
8- **Mechanisms of suppression of GVHD.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. March 22nd 2010
9- **Signaling control of B cell activation.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. March 29th 2010
10- **Optimization of Dendritic Cell Based Vaccines.** Rosenstiel Medical Science Building, University of Miami, Miami, FL., USA. April 5th 2010
11- **How to write a successful proposal.** Faculty of Science, Tanta University, Tanta, Egypt. June 15 - 16, 2010
12- **Characterization of novel huCD16a (FcyRIIIA) transgenic mouse for preclinical assessment of therapeutic ADCC-mediating antibodies.** Renaissance Eden Roc Resort, Miami, FL, USA December 1st 2010
13- **Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.** Renaissance Eden Roc Resort, Miami, FL, USA December 1st 2010
14- **SHP2 regulates pSTAT1-mediated APM component expression and CTL recognition of head and neck cancer cells**. Renaissance Eden Roc Resort, Miami, FL, USA December 1st 2010
15- **Spatial and temporal regulation of CXCR3 chemokine production and CD8 T cell infilteration in the metastatics melanoma microenvironment**. Renaissance Eden Roc Resort, Miami, FL, USA December 1st 2010
16- **Deletion of TGF-β receptor promotes mammary carcinoma progression by enhanced Th17 response**. Renaissance Eden Roc Resort, Miami, FL, USA December 2nd 2010
17- **Regulatory T cells are dependent on P13K pathway allowing for their selective inhibition in vivo.** Renaissance Eden Roc Resort, Miami, FL, USA December 2nd 2010
18- **The identification of two functionally distinct subsets (Treg and Teff) within the human CD4+CD39+ T cells population.** Renaissance Eden Roc Resort, Miami, FL, USA December 2nd 2010
19- **Galectin-1 modulates tolerance in neuroblastoma.** Renaissance Eden Roc Resort, Miami, FL, USA December 2nd 2010
20- **"Adoptive Therapy for Cancer: CARs Beginning to Work?"** Sylvester Comprehensive Cancer Center. University of Miami, Miami, FL., USA March 04, 2011
21- **"How to write a TEMPUS proposal"**: December 10, 2012, Faculty of Medicine, Tanta University, Egypt.

LANGUAGE SKILLS

- Arabic: Native
- English: Fluent in reading, writing and speaking

COMPUTER SKILLS:

- ICDL (International computer driving licenses)
- Experienced user of Macintosh (Mac), Windows, and Keen user to the Internet

TV INTERVIEWS

- Channel 7, Miami, USA, Experimental drug enhances breast cancer chemotherapy side effects, November 2009.
- Coral Gables TV, Miami, USA, latest discoveries in fighting against cancer, September 2010. http://www.youtube.com/watch?v=r-mWu6uf7YA

CONFERENCES COMMITTEES

1. **Coordinator,** The 1st Annual Conference of the Center of Excellence in Cancer Research (CECR), Next Generation Cancer Research and Diagnosis, Tanta University, Egypt. February 24, 2014.

2. **Organizing Committee**: The 1st annual conference of postgraduate students of science (PSS-2013) (Technology and future scientists), Faculty of Science, Tanta University, Egypt. May 5, 2013. http://www.tanta.edu.eg/ar/Conf/research2013/index.html

3. **Organizing Committee**: The 3rd conference on Enhancing Scientific Research, Tanta University, Egypt, from 18-19 November 2012. http://www.tanta.edu.eg/ar/conf3_res.html

INVITED TALKS:

1. **Generation of T cells with stem cell–like phenotype for anti-tumor adoptive immunotherapy**. The 1st annual conference of postgraduate students of science (PSS-2013) (Technology and future scientists), Faculty of Science, Tanta University, Egypt. May 5, 2013

2. **Development of a Novel Biopolymer Delivery System for DNA Vaccines and Adjuvants**. The 28th Annual congress of Tanta Faculty of Medicine (Quailty and medicine). March 4- 8, 2013, Tanta, Egypt

3. **Immunomodulatory effects of IL-12 released from poly-N-acetyl glucosamine gel matrix during schistosomiasis infection**. The 28th Annual congress of Tanta Faculty of Medicine (Quailty and medicine). March 4- 8, 2013, Tanta, Egypt

4. **Reprogramming tumor-reactive $CD8^+$ T cells by IL-12 to acquire stem cell-like phenotype in vitro mediates tumor eradication upon adoptive transfer into a lymphopenic host**. The

28th Annual congress of Tanta Faculty of Medicine (Quailty and medicine). March 4- 8, 2013, Tanta, Egypt

5. **Anti-tumor response, homing, persistence, and differentiation of adoptively transferred tumor antigen-reactive CD8+ T cells into memory cells are independent of the homing receptor CD62L**. The 7th International Conference on Biological Sciences, December 5-6, 2012, Tanta University, Tanta, Egypt

6. **Using biotechnological approach for mRNA-based vaccination in cancer immunotherapy.** The 3rd conference on Enhancing Scientific Research, Tanta University, Egypt, 19 November 2012

7. **The use of stem cells from Egyptian patients with chronic HCV to generate functional dendritic cells for immunotherapy.** The 3rd conference on Enhancing Scientific Research, Tanta University, Egypt, from 18 November 2012

8. **CD62L is not required for the generation and maintenance of protective anti-tumor memory CD8+ T cells**. The 13th Annual Zubrod Memorial lecture and Sylvester Cancer Research Poster Session, May 18, 2012, Miami, FL, USA

CONFERENCES: ABSTRACTS AND POSTER PRESENTATION

1. C. Marcela Díaz-Montero, Antonio Perez, **Abdel-Aziz Zidan**, Christopher J. Pazoles, Alberto J. Montero. Immunomodulatory activity of NOV-002 potentiates the anti-tumor efficacy of cyclophosphamide (CTX) in the CT26 murine colon cancer model. 101st Annual Meeting for American Association for Cancer Research (AACR), April 17-21, 2010, Washington, DC, USA

2. **Abdel-Aziz Zidan**, Alberto J. Montero, C. Marcela Diaz-Montero. Generation of memory $CD8^+$ T cells against tumor antigens is independent of CD62L. American Association for Cancer Research (AACR) Tumor Immunology: Basic and Clinical Advances conference, November 30-December 3, 2010, Miami, FL, USA

3. C. Marcela Diaz-Montero, **Abdel-Aziz Zidan**, John Vournakis, and Alberto J. Montero. Nano polymer-based Platform for the Delivery of DNA vaccines and adjuvants, The 2nd international Circular and Provisional Conference Programme for gene-based vaccines, November 8-10, 2010, the Novotel Cannes Montfleury, Cannes, France

4. C. Marcela Diaz-Montero, Osama Naga, **Abdel-Aziz A. Zidan**, Mohamed L. Salem, Maria Pallin, Anita Parmigiani, Gail Walker,§ Eric Wieder, Krishna Komanduri, David J. Cole, Alberto J. Montero, Mathias G. Lichtenheld. persistent tumor clearance after transfer of IL-12 primed

CTL into lymphdepleted host, Cancer Immunotherapy 2011: Immune Effector Mechanisms in Tumor Immunity: October 3-5, 2011, New York City, USA

5. Tadeu Ambros, **Abdel-Aziz A. Zidan**, Maria Pallin, Alberto Montero, Mathias Lichtenheld, Marcela C. Díaz-Montero: High affinity T cell receptor (TCR) gives advantage to the homeostatic proliferation of naive CD8 T cells only under competitive pressure, The 99th American Association of Immunologists annual meeting: IMMUNOLOGY 2012, May 4-8, 2012, Boston, Massachusetts, USA

6. **Abdel-Aziz A. Zidan**, Maria Pallin, Mohamed L. Salem, Alberto Montero, Mathias Lichtenheld, C. Marcela Díaz-Montero: CD62L is not required for the generation and maintenance of protective anti-tumor memory $CD8^+$ T cells. The 13th Annual Zubrod Memorial lecture and Sylvester Cancer Research Poster Session, May 18, 2012, Miami, FL, USA

7. Tadeu Ambros, **Abdel-Aziz A. Zidan**, Maria Pallin, Alberto Montero, Mathias Lichtenheld, Marcela C. Díaz-Montero: High affinity T cell receptor (TCR) gives advantage to the homeostatic proliferation of naive CD8 T cells only under competitive pressure, The 13th Annual Zubrod Memorial lecture and Sylvester Cancer Research Poster Session, May 18, 2012, Miami, FL, USA

8. John M. Goldberg**, Abdel-Aziz A. Zidan**, Rabia Siddiqi, Myriam Zayas, Camille D. Brown, David A. Ludwig, Alberto J. Montero, C Marcela Diaz-Montero: Measurement of numbers of myeloid derived suppressor cells in healthy children and children with cancer. The 48th Annual Meeting, American Society of Clinical Oncology. June 1-5, in Chicago, Illinois, USA

9. **Abdel-Aziz A. Zidan**, Maria Pallin, Alberto J. Montero, Mathias G. Lichtenheld, C. Marcela Díaz-Montero, Mohamed L. Salem. Anti-tumor response, homing, persistence, and differentiation of adoptively transferred tumor antigen-reactive $CD8^+$ T cells into memory cells is independent of the homing receptor CD62L. The 7th International Conference on Biological Sciences, December 5-6, 2012, Tanta University, Tanta, Egypt

10. Mohamed L. Salem, **Abdel-Aziz A. Zidan**, Maria Pallin, Alberto J. Montero,C. Marcela Diaz-Montero: Treatment with IL-12 Induces Acquisition of Stem Cell-Like Phenotype by Early But not Late Melanoma-Reactive $CD8^+$ T Cells That Mediate Tumor Eradication Upon Adoptive Transfer into a Lymphopenic Host. International conference of Arabic Foundation for Molecular Genetic & Stem Cell. Feb 20- 21, 2013, Grand Hayat Hotel, Cairo, Egypt

11. Mohamed L. Salem, **Abdel-Aziz A. Zidan**, Maria Pallin, Alberto J. Montero,C. Marcela Diaz-Montero: Reprogramming tumor-reactive $CD8^+$ T cells by IL-12 to acquire stem cell-like phenotype in vitro mediates tumor eradication upon adoptive transfer into a lymphopenic host.

The 28th Annual congress of Tanta Faculty of Medicine (Quailty and medicine). March 4- 8, 2013, Tanta, Egypt

12. Mohamed L. Salem, Nahla M. Shoukry, **Abdel-Aziz A. Zidan**, John Vournakis: Immunomodulatory effects of IL-12 released from poly-N-acetyl glucosamine gel matrix during schistosomiasis infection. The 28th Annual congress of Tanta Faculty of Medicine (Quailty and medicine). March 4- 8, 2013, Tanta, Egypt

13. **Abdel-Aziz A. Zidan**, Mohaamed L. Salem, Alberto J. Montero, John Vournakis, C.Marcela Diaz-Montero: Development of a Novel Biopolymer Delivery System for DNA Vaccines and Adjuvants. The 28th Annual congress of Tanta Faculty of Medicine (Quailty and medicine). March 4- 8, 2013, Tanta, Egypt

14. Mohamed L. Salem, **Abdel Aziz A. Zidan**, Abdel Raouf Abou Al-Azm, Maha Aldemelaawy, Hasan Albate, Mohamed Attia, Mohamed Abou Senna. Frequencies of circulating myeloid derived suppressor cells and dendritic cells in Egyptian patients with chronic hepatitis c virus infection undergoing treatment with IFN-α-based therapy. Montreal 2013 international forum on Immunology. October 19-20, 2013. Montreal, Canada.

15. Mohamed L. Salem, **Abdel Aziz A. Zidan**, Abdel Raouf Abou Al-Azm, Maha Aldemelaawy, Hasan Albate, Mohamed Attia, Mohamed Abou Senna. Frequencies of circulating myeloid derived suppressor cells and dendritic cells in Egyptian patients with chronic hepatitis c virus infection undergoing treatment with IFN-α-based therapy. The 28th Annual Meeting of Society for Immunotherapy of Cancer, from 8-10 November, 2013 in National Harbor, MD, USA.

16. **Abdel-Aziz A. Zidan**, C. Marcela Díaz-Montero, Maria Pallin, Alberto J. Montero, Mathias G. Lichtenheld, Mohamed L. Salem. Generation of T cells with stem cell–like phenotype for anti-tumor adoptive immunotherapy. Submitted to the 29th Annual congress of Tanta University, Faculty of Medicine (Multidisciplinary Medicine Era). 17- 20 March, 2014, Tanta, Egypt

17. **Abdel-Aziz A. Zidan**, C. Marcela Díaz-Montero, Maria Pallin, Alberto J. Montero, Mathias G. Lichtenheld, Mohamed L. Salem. Down-regulation of the homing receptor CD62L is not essential for the anti-tumor responses of adoptively transferred IL-12 ex vivo-expanded CD8+ T cells. Submitted to the 29th Annual congress of Tanta University, Faculty of Medicine (Multidisciplinary Medicine Era). 17- 20 March, 2014, Tanta, Egypt

18. Mohamed Salem, **Abdel Aziz A. Zidan**, Guillermo Rivell and David Cole. Enhancing anti-cancer adoptive T cell therapy by triggering toll-like receptors signaling pathways. Submitted to the 29th Annual congress of Tanta University, Faculty of Medicine (Multidisciplinary Medicine Era). 17- 20 March, 2014, Tanta, Egypt

BIBLIOGRPAHY

A. Non-Peer reviewed Articles:

These articles are written in Arabic and the titles below were translated:

1. Mohamed L. Salem and **Abdel Aziz A. Zidan**: Strengthen your immunity by Ramadan Fasting, Arab Community Scientific Organization. July 31, 2013. http://www.arsco.org/Home/Details?entityID=9bf2ecd5-9585-4540-942d-6ad623370659&resourceId=9ae5e27f-8341-4b70-a180-f75949585099

B. Book Chapters:

1. Mohamed Labib Salem, Said M. Hammad, Mohamed R. El-shanshory, Mohamed A. Attia and **Abdel-Aziz A. Zidan**: "Immunostimulatory Effects of Triggering TLR3 Signaling Pathway - Implication for Cancer Immunotherapy" in "Immune Response Activation", ISBN: ISBN 978-953-51-1374-4, 274 pages, Publisher: InTech, Chapters published May 29, 2014 under CC BY 3.0 license. DOI: 10.5772/57004. http://www.intechopen.com/books/immune-response-activation/immunostimulatory-effects-of-triggering-tlr3-signaling-pathway-implication-for-cancer-immunotherapy

C. Published Abstract:

1. Mohamed L Salem, **Abdel-Aziz A Zidan**, Mohamed Abou Senna, Abdel Raouf Abou Al-Azm, Hasan Albatei, Maha Aldemelaawy, Mohamed Attia. Frequencies of circulating myeloid derived suppressor cells and dendritic cells in Egyptian patients with chronic Hepatitis C Virus infection undergoing treatment with IFN-a-based therapy. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P248 (http://www.immunotherapyofcancer.org/content/1/S1/P248). From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. 8-10 November 2013.

2. John M Goldberg, **Abdel-Aziz Zidan**, Rabia Siddiqi, Myriam Zayas, Camille D Brown, Lourdes Forster, David A Ludwig, Alberto J Montero, C Marcela Diaz-Montero. Circulating myeloid-derived suppressor cells in pediatric solid tumor patients. AMER SOC CLINICAL ONCOLOGY (ASCO), 20/5/2012. Volume 13, Issue 15. (IF= 18.038). http://meetinglibrary.asco.org/content/92974-114

D. Original Articles:

1. C. Marcela Díaz-Montero, **Abdel-Aziz Zidan**, Maria F. Pallin, Vasileios Anagnostopoulos, Mohamed L. Salem, Eric Wieder, Krishna Komanduri, Alberto J. Montero, Mathias G. Lichtenheld. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell

therapy: role of CD62L. Immunol Res. December 2013, Volume 57, Issue 1-3, pp 23-33 Dec;57(1-3):23-33. doi: 10.1007/s12026-013-8456-1. (IF= 2.963)

2. Muobarak J. Tuorkey, Karolin K. Abdul-Aziz, **Abdel-Aziz A. Zidan**. Active Immunization Against Tumor Necrosis Factor-alpha Decreases Proinflammatory Cytokines, Oxidative Stress Mediators and Adhesion Molecules Risk Factors in Streptozotocin-induced Diabetic Rats. Endocr Metab Immune Disord Drug Targets. 2013 Sep; 13(3):269-74.

3. Mohamed L. Salem, Nahla M. Shoukry, **Abdel-Aziz A. Zidan**, John Vournakis: Immunomodulatory effects of IL-12 released from poly-N- acetyl glucosamine gel matrix during schistosomiasis infection. Cytotechnology. 2013 Jul 26. [Epub ahead of print]. (IF= 1.315)

4. Mohamed L. Salem, Amir A. Al-Khami, Sabry A. El-Nagaar, **Abdel-Aziz A. Zidan**, Ismail M. Al-Sharkawi, C. Marcela Díaz-Montero, David J. Cole: Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with Cyclophosphamide. Cell Immunol. 2012 Mar-Apr; 276 (1-2):67-74. (IF= 1.974)

5. C. Marcela Diaz-Montero, Yong Wang, Lijian Shao, Wei Feng, **Abdel-Aziz A. Zidan**, Cristopher J Pazoles,Alberto J. Montero, Daohong Zhou: The glutathione disulfide mimetic, NOV-002, inhibits cyclophosphamide induced hematopiotic and immune suppression by reducing oxidative stress. Free RadicBiol Med. 2012 May 1; 52(9):1560-8. Epub 2012 Feb 15. (IF= 5.423)

6. C. Marcela Diaz-Montero, Osama Naga, **Abdel-Aziz A. Zidan**, Mohamed L. Salem, Maria Pallin, Anita Parmigiani, Gail Walker,§ Eric Wieder, Krishna Komanduri, David J. Cole, Alberto J. Montero, Mathias G. Lichtenheld: Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. Am J Cancer Res. 2011; 1 (7): 882–896. (IF= 2.651)

REFERENCES

- **Mohamed Labib Salem, Ph.D**.
  Professor of Immunology, Immunology & Biotechnology Unit (IBT), Zoology Department, Faculty of Science, Tanta University, Egypt
  Director, Center of Excellence in Cancer Research (CECR)
  Director, Grants, Innovation & Technology Transfer Center (GITTC)
  Tanta University, Egypt
  E-mail: mohamedlabibsalem@yahoo.com, mohamed.labib@science.tanta.edu.eg,

- **Claudia Marcela Diaz-Montero, Ph.D**.
  Research Assistant Professor, Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, United States of America.
  E-mail: diazc2@ccf.org

- **Alberto J. Montero, M.D**.
  Assistant Professor of Clinical Medicine, Department of Solid Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, United States of America.
  E-mail: Amontero@med.miami.edu